drugset / Trial / NCT03799848
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
SequentialOpen-labelBasic science
Summary
This is a Phase I open-label study to evaluate the pharmacokinetic (PK) profile of a single oral dose of vadadustat in subjects with hepatic impairment(HI) compared to healthy matched control subjects with normal hepatic function.
Timeline
- Start
- 2018-06-12
- Primary completion
- 2018-10-18
- Completion
- 2018-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vadadustat | Small molecule | 450 mg | Oral |
Indications
No indication recorded.